Apnimed, Inc. (APMD) stock
APMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026
$17.80+1.52 (+9.34%)
Close on Nov 17, 2026Market cap $85.47MP/E –Yield –
Apnimed r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.90M | – |
| Q2 FY2025 | Jun 30, 2025 | $15.97M | – |
See a number that looks wrong?